Artificial Intelligence to discover and validate new therapeutic targets in cancer
We help you to:
Identify a new Therapeutic Target
Identify a Lead Compound
Determine the Mechanism of Action of a given compound
CancerAppy is a biotech specialized in the field of cancer research, focused on the discovery and development of new therapeutic targets, based on its own artificial intelligence methodology
Cancer: a global problem
Cancer is a global problem and the identification of novel therapies is an urgent need. Unfortunately, drug development is a long lasting and expensive process with a high risk of failure.
Incorporation of targeted therapies challenge physicians and healthcare providers to adapt their systems to provide an easy and sustainable access to personalize medicine.
Better medicines for a personalized care
CancerAppy aims to resolve this problem by de-escalating the risk of drug development helping healthcare providers to optimize and improve their services.
By using big data, machine learning and biology at a global scale, CancerAppy seeks to enable better medicines for a personalized care.
We do work at four different scales in an integrated manner by using global biology data, therapeutic structural efficacy information, machine learning and real world patient data.
Our style: Where science meets artificial intelligence
Our team at CancerAppy is highly diversified, with practical experience, profound knowledge and subject matter expertise in oncology research, patient care and computer science. This enables us to provide cutting edge solutions, using science and artificial intelligence, at a global scale to hospitals, academic institutions, pharmaceutical companies and a wide range of players involved in patient care and cancer research.
Transforming the world of cancer research
With our platform we fill the gap between basic data and pharma intelligence tools. Our mission is to empower scientists, researchers, physicians and healthcare providers with the global benchmark in cancer research and patient treatment. This will let us transform the world of cancer research and eventually improve the lives of millions of people, globally.
Thanks to our deep knowledge and expertise in oncology and AI, we use a massive amount of multimodal data in our state-of-the-art AI algorithms, helping to identify new therapeutic targets, identify lead compounds, and determine the mechanism of action of a given compound. as well as possible drug combinations.
Request a Demo
We would be happy to help you.
Our AI Platform comprises of DrugOptimization to identify and validate novel targets and/or identify the mechanism of action of a compound, DrugCombination to explore potential drug combinations providing a score for the mixed drugs, and GeneReport which is a personalized treatment matched application that permits score predicted treatments with patient genomic actionable information.
Latest news about CancerAppy…
In the early stages, 97% of drug development fails. The discovery and development of a new cancer drug is a long, costly, and high-risk process. The estimated time to develop a new cancer drug exceeds 10 years, costs 2 billion EUR or more, and yet only 4% of the new...
CancerAppy was present at Anglonordic 2022. An event in which we had the opportunity to contact investors and companies in the biotechnology sector and present our research projects.
We are going to stay in Tel Aviv from March 25th through March 28th looking to learn about entrepreneurship, new relationships and visiting investors.
Subvencionado por el CDTI
Somos cliente Enisa